Prasinezumab, an experimental monoclonal antibody treatment, may help reduce the deterioration of motor skills in people with rapidly progressing Parkinson’s disease, a new study suggests.

Related Keywords

Steve Allder , Daniel Truong , Cognition Health , Medical News Today , Truong Neuroscience Institute , Memorialcare Orange Coast Medical Center , Fountain Valley , Clinical Parkinsonism , Related Disorders ,